An Open-Label Study to Investigate the Pharmacodynamics of a Repeat Dose Regimen of Bevacizumab (10mg/kg q2w) and Escalating Repeat Doses of Pazopanib in Renal Cell Carcinoma.
Phase of Trial: Phase I
Latest Information Update: 15 Nov 2017
At a glance
- Drugs Bevacizumab (Primary) ; Pazopanib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 14 Mar 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 18 Oct 2013 Planned end date changed from 1 Apr 2013 to 1 Nov 2013 as reported by ClinicalTrials.gov.
- 22 Feb 2013 Planned end date changed from 1 Oct 2012 to 1 Apr 2013 as reported by ClinicalTrials.gov.